InsiderSignalSign in

← Insider buys

Randal J Kirk has bought stock on 21 days since May 2016

Director and 10% owner at Precigen, Inc., and 9 other companies

SEC CIK 0001091823 · Filings on SEC.gov ↗

$238.4MBought

$125.4MSold

Aug 13Last buy

Randal J Kirk's record

3 months after each buy, from the first price a copier could get.

−14.2%Average

−18.1 ptsVs S&P 500

2 of 6Higher

6 buys since 2016 with 3 months of prices.

Companies

Every filing

36 filings since May 2016, newest first

Precigen, Inc.

Director and 10% owner

$15.8M−4.0%Mar 31

Precigen, Inc.

Director and 10% owner

$7.9M−2.0%Dec 22

Precigen, Inc.

Director and 10% owner

$12.3M−2.0%Nov 21

Precigen, Inc.

Director and 10% owner

$20.0M+25.0%Aug 13

Precigen, Inc.

Director and 10% owner

Precigen, Inc.

Director and 10% owner

$758K+1.0%Aug 17

Precigen, Inc.

Director and 10% owner

$20.0M+14.0%Jan 31

Aquabounty Technologies, Inc.

10% owner

$27.0M−71.0%Nov 24

Precigen, Inc.

Director and 10% owner

$3.6M+2.0%Nov 23

Aquabounty Technologies, Inc.

10% owner

$10.0M+28.0%Aug 13

Precigen, Inc.

Executive Chair and 10% owner

$5.3M+5.0%Aug 13

Precigen, Inc.

Executive Chair and 10% owner

$2.2M+1.0%Mar 20

Aquabounty Technologies, Inc.

10% owner

$7.8M+57.0%Feb 18

Precigen, Inc.

Executive Chair and 10% owner

$35.0M+8.0%Feb 4

Intrexon Corp

CEO and 10% owner

$1.7M+1.0%Jun 10

Intrexon Corp

CEO and 10% owner

Intrexon Corp

CEO and 10% owner

$1.3M+1.0%May 24

Intrexon Corp

CEO and 10% owner

$2.0M+1.0%May 21

Intrexon Corp

CEO and 10% owner

$3.7M+2.0%May 15

Synthetic Biologics, Inc.

10% owner

$99K−40.0%Apr 3

Histogenics Corp

10% owner

$159K−37.0%Jan 15

Halozyme Therapeutics Inc

10% owner

$11.7M−4.0%Aug 28

Halozyme Therapeutics Inc

10% owner

$21.1M−7.0%Aug 23

Halozyme Therapeutics Inc

10% owner

$8.5M−3.0%Aug 16

Halozyme Therapeutics Inc

10% owner

$9.9M−3.0%Aug 10

Halozyme Therapeutics Inc

10% owner

$5.2M−2.0%Jul 27

Intrexon Corp

CEO and 10% owner

$100.0M+13.0%Jul 6

Halozyme Therapeutics Inc

10% owner

$5.2M−2.0%Jun 29

Intrexon Corp

CEO and 10% owner

$12.5M+2.0%Jan 22

Aquabounty Technologies, Inc.

10% owner

$5.0M+26.0%Jan 19

Fibrocell Science, Inc.

10% owner

$2.1M+49.0%Dec 13

Intrexon Corp

CEO and 10% owner

Soligenix, Inc.

10% owner

$502K−23.0%May 8

Ampliphi Biosciences Corp

10% owner

$84K−11.0%Dec 29

Oragenics Inc

10% owner

$1.2M+17.0%Jul 5

Intrexon Corp

CEO and 10% owner

About Randal J Kirk

Randal J. Kirk is a prominent biotech investor and director serving as a 10% owner and director of Precigen Inc. (NASDAQ: PGEN)( a regenerative medicine and synthetic biology company. Kirk has demonstrated significant commitment to Precigen's long-term growth through substantial capital investments, including a $20 million purchase of 23.52 million shares in August 2024, signaling strong management confidence in the company's prospects( As of early 2026, Kirk controls approximately 116 million shares of Precigen worth over $458 million through various entities he manages, including trusts and limited liability companies(

Beyond Precigen, Kirk maintains a diversified portfolio of biotech investments, serving as a 10% owner of AquaBounty Technologies Inc. (NASDAQ: AQB) and holding ownership stakes in other life sciences ventures including Translate Bio Inc. and FibroCell Science Inc.( His investment strategy reflects a pattern of active insider participation, combining substantial share purchases during growth phases with strategic sales during market peaks—including notable sales totaling over $15.7 million in March 2026( Kirk's extensive involvement across multiple biotechnology companies and his history of significant capital deployment underscore his role as a major player in the regenerative medicine and synthetic biology sectors.

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.